CY1107989T1 - Ανασυνδυασμενα αντισωματα της ανθρωπινης ιντepλευκινης-1 βητα - Google Patents

Ανασυνδυασμενα αντισωματα της ανθρωπινης ιντepλευκινης-1 βητα

Info

Publication number
CY1107989T1
CY1107989T1 CY20061101860T CY061101860T CY1107989T1 CY 1107989 T1 CY1107989 T1 CY 1107989T1 CY 20061101860 T CY20061101860 T CY 20061101860T CY 061101860 T CY061101860 T CY 061101860T CY 1107989 T1 CY1107989 T1 CY 1107989T1
Authority
CY
Cyprus
Prior art keywords
human
intelephein
antibodies
beta
recovery
Prior art date
Application number
CY20061101860T
Other languages
English (en)
Inventor
Hermann Gram
Padova Franco E Di
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9884137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1107989(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1107989T1 publication Critical patent/CY1107989T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)

Abstract

Παρέχεται ένα μόριο πρόσδεσης ΙL-1β, συγκεκριμένα ένα αντίσωμα της ανθρώπινης IL-1β, ιδιαίτερα ένα ανθρώπινο αντίσωμα της ανθρώπινης IL-1β, στο οποίο οι CDRs της βαριάς και της ελαφριάς αλυσίδας έχουν αλληλουχίες αμινοξέων όπως ορίστηκαν, για χρήση στην θεραπεία μιας IL-1 μεσολαβούμενης ασθένειας ή διαταραχής, π.χ. της οστεοαρθρίτιδας, της οστεοπόρωσης και άλλων φλεγμονωδών αρθρίτιδων.
CY20061101860T 2000-01-21 2006-12-29 Ανασυνδυασμενα αντισωματα της ανθρωπινης ιντepλευκινης-1 βητα CY1107989T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0001448.0A GB0001448D0 (en) 2000-01-21 2000-01-21 Organic compounds
EP01905671A EP1248804B2 (en) 2000-01-21 2001-01-19 Recombinant antibodies to human interleukin-1 beta

Publications (1)

Publication Number Publication Date
CY1107989T1 true CY1107989T1 (el) 2013-09-04

Family

ID=9884137

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101860T CY1107989T1 (el) 2000-01-21 2006-12-29 Ανασυνδυασμενα αντισωματα της ανθρωπινης ιντepλευκινης-1 βητα

Country Status (33)

Country Link
US (4) US20030124617A1 (el)
EP (1) EP1248804B2 (el)
JP (2) JP3978338B2 (el)
KR (1) KR100697126B1 (el)
CN (1) CN1395581B (el)
AR (1) AR027253A1 (el)
AT (1) ATE346868T1 (el)
AU (1) AU772949B2 (el)
BR (1) BR0107661A (el)
CA (1) CA2396212C (el)
CO (1) CO5261584A1 (el)
CY (1) CY1107989T1 (el)
CZ (1) CZ302738B6 (el)
DE (1) DE60124863T3 (el)
DK (1) DK1248804T4 (el)
ES (1) ES2274865T5 (el)
GB (1) GB0001448D0 (el)
HK (1) HK1050013A1 (el)
HU (1) HUP0204156A3 (el)
IL (2) IL150551A0 (el)
MX (1) MXPA02007091A (el)
MY (1) MY155269A (el)
NO (1) NO329816B1 (el)
NZ (1) NZ519936A (el)
PE (1) PE20011219A1 (el)
PL (1) PL207642B1 (el)
PT (1) PT1248804E (el)
RU (1) RU2264413C2 (el)
SI (1) SI1248804T2 (el)
SK (1) SK288054B6 (el)
TR (1) TR200201780T2 (el)
WO (1) WO2001053353A2 (el)
ZA (1) ZA200205659B (el)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
PE20020132A1 (es) 2000-06-29 2002-03-04 Abbott Lab Anticuerpos de especificidad doble y metodos para la elaboracion y el uso de los mismos
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
CN1652821A (zh) * 2002-01-28 2005-08-10 米德列斯公司 抗前列腺特异性膜抗原(psma)的人单克隆抗体
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
EP2280285A1 (en) * 2003-09-15 2011-02-02 Oklahoma Medical Research Foundation Method of using cytokine assays to diagnose, treat, and evaluate inflammatory and autoimmune diseases
KR20120083534A (ko) * 2004-02-06 2012-07-25 메다렉스, 인코포레이티드 클로스트리듐 디피실리 독소에 대한 항체 및 이의 용도
AU2006208286A1 (en) 2005-01-26 2006-08-03 Amgen Fremont Inc. Antibodies against interleukin-1 beta
PE20061324A1 (es) * 2005-04-29 2007-01-15 Centocor Inc Anticuerpos anti-il-6, composiciones, metodos y usos
SI2314623T1 (sl) * 2005-06-21 2012-11-30 Xoma Technology Ltd IL beta vezavna protitelesa in njihovi fragmenti
PT1940465E (pt) 2005-10-26 2012-10-03 Novartis Ag Nova utilização para compostos de il-1 beta
HUE034269T2 (en) 2005-12-29 2018-02-28 Janssen Biotech Inc Human anti-IL-23 antibodies, preparations, methods and applications
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
CA2648223A1 (en) * 2006-04-14 2007-10-25 Novartis Ag Use of il-i antibodies for treating ophthalmic disorders
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US7695718B2 (en) 2006-12-20 2010-04-13 Xoma Technology Ltd. Methods for the treatment of IL-1β related diseases
US8324350B2 (en) * 2006-12-29 2012-12-04 Abbott Laboratories Dual-specific IL-1α/IL-1β antibodies
EP2417974A1 (en) 2007-02-28 2012-02-15 Schering Corporation Combination therapy for treatment of immune disorders
BRPI0812040A2 (pt) * 2007-05-29 2014-10-21 Novartis Ag Indicações para terapia de anti-il-i-beta
MX2010006823A (es) * 2007-12-20 2010-09-30 Xoma Technology Ltd Metodos para el tratamiento de la gota.
DK2293816T3 (da) * 2008-06-06 2013-02-04 Xoma Technology Ltd Fremgangsmåder til behandling af reumatoid arthritis
AU2009289547A1 (en) 2008-09-05 2010-03-11 Xoma (Us) Llc Methods for treating or preventing IL-1beta related diseases
JP5711751B2 (ja) 2009-10-26 2015-05-07 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ グリコシル化された免疫グロブリンの調製方法
SG2014014724A (en) * 2010-05-07 2014-07-30 Xoma Technology Ltd METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS
DE102010033565B4 (de) * 2010-07-27 2012-06-21 Tetec Tissue Engineering Technologies Ag Marker zur Bestimmung von Chondrozyten
RU2750219C2 (ru) 2010-08-02 2021-06-24 Ридженерон Фармасьютикалз, Инк. Мыши, у которых вырабатываются связывающие белки, содержащие vl-домены
NZ607510A (en) * 2010-09-10 2014-10-31 Apexigen Inc Anti-il-1 beta antibodies and methods of use
RS59661B2 (sr) 2011-02-25 2023-06-30 Regeneron Pharma Adam6 miševi
MY172718A (en) 2011-08-05 2019-12-11 Regeneron Pharma Humanized universal light chain mice
DE102011083595A1 (de) 2011-09-28 2013-03-28 Bayer Pharma AG Inhibition der Wirkung von Interleukin 1 beta zur Behandlung der Endometriose
US20150017157A1 (en) 2011-12-19 2015-01-15 Xoma (Us) Llc Methods for treating acne
CA2859408C (en) 2011-12-20 2020-06-16 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
HUE049860T2 (hu) 2012-02-13 2020-11-30 Agency Science Tech & Res IL-ß-t neutralizáló, humán monoklonális antitestek
PL3597037T3 (pl) 2012-06-12 2021-10-25 Regeneron Pharmaceuticals, Inc. Humanizowane zwierzęta inne niż ludzie z ograniczonymi loci łańcucha ciężkiego immunoglobuliny
ES2762640T3 (es) 2014-03-21 2020-05-25 Regeneron Pharma Proteínas VL de unión a antígeno que exhiben diferentes características de unión
WO2015143414A2 (en) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
CN107438622A (zh) 2015-03-19 2017-12-05 瑞泽恩制药公司 选择结合抗原的轻链可变区的非人动物
CN110818793A (zh) * 2018-08-14 2020-02-21 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
KR20210093973A (ko) 2018-11-20 2021-07-28 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 건선을 치료하는 안전하고 효과적인 방법
BR112021023295A2 (pt) 2019-05-23 2022-02-08 Janssen Biotech Inc Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772685A (en) 1985-10-02 1988-09-20 Merck & Co., Inc. Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
US4935343A (en) * 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
FR2640146B1 (fr) * 1988-12-08 1993-12-24 Commissariat A Energie Atomique Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
JP3714683B2 (ja) * 1992-07-30 2005-11-09 生化学工業株式会社 抗リウマチ剤
US5429614A (en) 1993-06-30 1995-07-04 Baxter International Inc. Drug delivery system
WO1995001997A1 (en) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
CO5261584A1 (es) 2003-03-31
RU2002121649A (ru) 2004-03-10
PE20011219A1 (es) 2001-12-17
ATE346868T1 (de) 2006-12-15
US20090232803A1 (en) 2009-09-17
CN1395581B (zh) 2010-10-13
SI1248804T1 (sl) 2007-06-30
MXPA02007091A (es) 2002-12-13
SK10352002A3 (sk) 2003-03-04
PL356297A1 (en) 2004-06-28
DK1248804T4 (da) 2010-04-06
WO2001053353A2 (en) 2001-07-26
CN1395581A (zh) 2003-02-05
ZA200205659B (en) 2003-12-31
NZ519936A (en) 2004-02-27
JP2007097598A (ja) 2007-04-19
SK288054B6 (sk) 2013-03-01
CA2396212C (en) 2013-04-02
JP2003520595A (ja) 2003-07-08
SI1248804T2 (sl) 2010-04-30
KR100697126B1 (ko) 2007-03-20
CA2396212A1 (en) 2001-07-26
AR027253A1 (es) 2003-03-19
ES2274865T3 (es) 2007-06-01
IL150551A (en) 2010-11-30
HUP0204156A3 (en) 2005-09-28
JP3978338B2 (ja) 2007-09-19
WO2001053353A3 (en) 2002-04-04
DE60124863T3 (de) 2010-05-20
EP1248804B1 (en) 2006-11-29
ES2274865T5 (es) 2010-04-19
IL150551A0 (en) 2003-02-12
DK1248804T3 (da) 2007-02-26
CZ20022531A3 (cs) 2002-10-16
MY155269A (en) 2015-09-30
US7491392B2 (en) 2009-02-17
EP1248804B2 (en) 2009-12-02
GB0001448D0 (en) 2000-03-08
HUP0204156A2 (hu) 2003-03-28
TR200201780T2 (tr) 2003-01-21
PT1248804E (pt) 2007-02-28
KR20020073178A (ko) 2002-09-19
EP1248804A2 (en) 2002-10-16
BR0107661A (pt) 2002-11-19
HK1050013A1 (zh) 2003-06-06
RU2264413C2 (ru) 2005-11-20
DE60124863T2 (de) 2007-04-26
NO329816B1 (no) 2010-12-27
US20110182894A1 (en) 2011-07-28
PL207642B1 (pl) 2011-01-31
CZ302738B6 (cs) 2011-10-12
DE60124863D1 (de) 2007-01-11
US20030124617A1 (en) 2003-07-03
US20060251660A1 (en) 2006-11-09
NO20023266L (no) 2002-08-28
AU3369701A (en) 2001-07-31
NO20023266D0 (no) 2002-07-05
AU772949B2 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
CY1107989T1 (el) Ανασυνδυασμενα αντισωματα της ανθρωπινης ιντepλευκινης-1 βητα
CY1108779T1 (el) Αντισωματα για την ανθρωπινη il-1 βητα
CY1120723T1 (el) Ανταγωνιστικα αντισωματα il-17
ES2559429T3 (es) Anticuerpos anti-NGF humanizados
CY1123400T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1110134T1 (el) Αντισωματα ειδικα για το cd22 και η θεραπευτικη και διαγνωστικη χρηση τους
CY1110033T1 (el) Τεχνητα ανθρωπινα θεραπευτικα αντισωματα εναντια σε ισομορφες cd45
CY1111845T1 (el) Μορια δεσμευομενα me cd20
ECSP024210A (es) Moléculas de anticuerpo que tienen especificidad por el factor de necrosis tumoral alfa humano, y uso de las mismas
RS53318B (en) B-CELL REDUCTION BY USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES
RS53708B1 (en) ANTIBODY MOLECULES SPECIFIC TO HUMAN IL-6
ATE548386T1 (de) Synthetische immunglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
EP2305716A3 (en) Antibodies directed to gpnmb and uses thereof
EA200400510A1 (ru) Агенты, специфически связывающие ангиопоэтин-2
EA200501286A1 (ru) МОЛЕКУЛЫ АНТИТЕЛ СО СПЕЦИФИЧНОСТЬЮ К ЧЕЛОВЕЧЕСКОМУ IL-1β
NO20061070L (no) Antistoffer mot parathyoidhormon (PTH) og anvendelser derav
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
DK1572087T3 (da) Antistoffer med cancerantigen TMEFF2 og anvendelser deraf
DE50015463D1 (de) Inen cd16-rezeptor und ein cd30-oberflächenprotein
CY1105380T1 (el) Προτιμωμενα τμηματα της νευρικης νηματικης πρωτεϊνης και μεθοδοι χρησης αυτων
BR0116686A (pt) Anticorpos anti-cd28 silenciados e uso dos mesmos
ATE366746T1 (de) Gegen das semp1-protein gerichtete antikörper, verfahren zu deren herstellung, und deren anwendungen
CY1107785T1 (el) Χρηση του βασιλιξιμαμπ στη θεραπεια της ρευματοειδους αρθριτιδας ´η νοσων του δερματος